Zurzuvae Shortage Update: What Patients Need to Know in 2026

If you're struggling to access Zurzuvae (zuranolone) and wondering if there's a shortage, you're asking the right question—but the answer is more complicated than a simple yes or no. Here's the most current information on Zurzuvae availability in 2026 and what it means for you.

Is Zurzuvae Officially in Shortage in 2026?

No. As of 2026, Zurzuvae (zuranolone) is

not listed on the FDA's official drug shortage database. Sage Therapeutics and Biogen continue to manufacture and supply zuranolone, and the medication is available through the authorized specialty pharmacy network.

However, this doesn't mean every patient can easily access it. A combination of structural factors creates what many patients experience as a de facto shortage—real, practical barriers that make Zurzuvae feel as scarce as a drug that's actually in short supply.

Why Does Zurzuvae Feel Like It's in Shortage?

Several structural factors make Zurzuvae genuinely hard to access—even when supply exists:

• Specialty pharmacy-only distribution: Zurzuvae cannot be dispensed at retail pharmacies. It flows through a limited specialty pharmacy network that ships medication directly to patients.
• Prior authorization requirements: Most insurers require PA before covering Zurzuvae, a process that can take 3–14 days or longer.
• Step therapy policies: Some insurers require patients to first try and fail on an SSRI before approving Zurzuvae—an especially difficult requirement for women with severe, acute PPD.
• Schedule IV controlled substance status: Federal and state regulations governing controlled substances add extra steps to the prescription and dispensing process.
• Geographic gaps: In rural and underserved areas, access to authorized specialty pharmacies—or to prescribers familiar with the Zurzuvae submission process—may be limited.

What Happened to Zulresso (Brexanolone)?

An important update for 2026: Zulresso (brexanolone), which was the first FDA-approved PPD treatment (an IV infusion), was voluntarily withdrawn from the U.S. market as of January 1, 2025. The FDA formally withdrew its approval in April 2025. The manufacturer cited practical treatment limitations—including the need for a 60-hour hospital infusion, complex logistics, and high cost—as reasons for the withdrawal.

This makes Zurzuvae the

sole FDA-approved PPD-specific medication available in the United States as of 2026. That raises the stakes for women who cannot access it.

Insurance Coverage in 2026: What Has Changed?

Coverage for Zurzuvae has expanded since the drug's launch in December 2023. According to data from Sage and Biogen, approximately 95% of patients with commercial insurance or Medicaid have some level of coverage for Zurzuvae. The three largest pharmacy benefit managers (PBMs) include Zurzuvae on their formularies.

For patients with Medicare, Zurzuvae is typically listed on Tier 5 (specialty tier), which carries the highest cost-sharing. The manufacturer savings card cannot be used with Medicare.

38,440+ patients found their medications in stock

38K+

Find Zurzuvae In Stock Today →

What Patients Can Do Right Now

If you're struggling to access Zurzuvae, take these steps:

1. Call Sage Central (1-844-987-9882): Patient navigators can help you identify specialty pharmacies, resolve prior authorization issues, and enroll you in savings programs.
2. Request a formulary exception: If Zurzuvae isn't covered by your plan, your prescriber can submit a letter of medical necessity to request an exception.
3. Use medfinder: medfinder contacts specialty pharmacies on your behalf to check which ones can fill your prescription, and texts you the results—saving significant time.
4. Talk to your doctor about alternatives: If access is delayed, SSRIs like sertraline can begin providing some relief. See our guide to alternatives to Zurzuvae.

The Bottom Line for 2026

Zurzuvae is not in an official FDA shortage in 2026, but structural access barriers—specialty-only distribution, insurance hurdles, and controlled substance regulations—make it genuinely hard for many patients to fill. With the withdrawal of Zulresso from the market, Zurzuvae is the only FDA-approved PPD medication in the U.S., making access advocacy more important than ever. Patient support resources, insurance navigation, and services like medfinder exist specifically to bridge this gap.